Ryder, JW; Falcone, JF; Manro, JR; Svensson, KA; Merchant, KM (2006). „Pharmacological characterization of cGMP regulation by the biarylpropylsulfonamide class of positive, allosteric modulators of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors”. The Journal of Pharmacology and Experimental Therapeutics319 (1): 293–8. DOI:10.1124/jpet.106.105734. PMID16803862.
O'neill, MJ; Bleakman, D; Zimmerman, DM; Nisenbaum, ES (2004). „AMPA receptor potentiators for the treatment of CNS disorders”. Current drug targets. CNS and neurological disorders3 (3): 181–94. DOI:10.2174/1568007043337508. PMID15180479.
O'neill, MJ; Witkin, JM (2007). „AMPA receptor potentiators: application for depression and Parkinson's disease”. Current drug targets8 (5): 603–20. DOI:10.2174/138945007780618517. PMID17504104.
Ryder, JW; Falcone, JF; Manro, JR; Svensson, KA; Merchant, KM (2006). „Pharmacological characterization of cGMP regulation by the biarylpropylsulfonamide class of positive, allosteric modulators of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors”. The Journal of Pharmacology and Experimental Therapeutics319 (1): 293–8. DOI:10.1124/jpet.106.105734. PMID16803862.
O'neill, MJ; Bleakman, D; Zimmerman, DM; Nisenbaum, ES (2004). „AMPA receptor potentiators for the treatment of CNS disorders”. Current drug targets. CNS and neurological disorders3 (3): 181–94. DOI:10.2174/1568007043337508. PMID15180479.
O'neill, MJ; Witkin, JM (2007). „AMPA receptor potentiators: application for depression and Parkinson's disease”. Current drug targets8 (5): 603–20. DOI:10.2174/138945007780618517. PMID17504104.